Dupixent Approved In US As First New Targeted Therapy In Over Decade For Chronic Spontaneous Urticaria
View all comments(0)
April 18 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
DUPIXENT® (DUPILUMAB) APPROVED IN THE U.S. AS THE FIRST NEW TARGETED THERAPY IN OVER A DECADE FOR CHRONIC SPONTANEOUS URTICARIA (CSU)
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Trump Administration Brokers. Intel and Apple Reach Chipmaking Agreement, Shares Surge More Than 13%

Global First Storage ETF Surges 88% Five Weeks After Listing. Is It Too Late to Buy Now?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.